SCHEMBL5135486

SCHEMBL5135486

CCCCn1c(-c2ccccc2)nc(-c2ccccc2)c1CN(Cc1ccc(OC)cc1)Cc1cccc(OC(F)(F)F)c1

nearest known ligand 0.42

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
C5AR1 P21730 1/20 0.42
CETP P11597 4/20 0.38
CALM1 P0DP23 1/20 0.38
CAMKK2 Q96RR4 1/20 0.38
SCD O00767 1/20 0.37
TLR7 Q9NYK1 1/20 0.37
PPARG P37231 3/20 0.37
TRPC5 Q9UL62 1/20 0.37
CRHR1 P34998 1/20 0.36
PPARA Q07869 2/20 0.36
MMP13 P45452 1/20 0.36
NR3C1 P04150 1/20 0.36
LTB4R2 Q9NPC1 1/20 0.35
PIM1 P11309 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5134680 0.95 C5AR1 (0.43) C5AR1CETPTRPC5CRHR1NR3C1
SCHEMBL5136840 0.93 C5AR1 (0.41) C5AR1PPARGCRHR1PPARAMMP13
SCHEMBL652216 0.93 C5AR1 (0.42) C5AR1CETPCALM1CAMKK2TLR7
SCHEMBL648419 0.92 C5AR1 (0.46) C5AR1CALM1CAMKK2TLR7
SCHEMBL5138032 0.91 C5AR1 (0.43) C5AR1PPARGCRHR1PPARAMMP13
SCHEMBL649156 0.90 C5AR1 (0.42) C5AR1CALM1CAMKK2TLR7PPARG
SCHEMBL5135861 0.90 CRHR1 (0.44) C5AR1CETPPPARGTRPC5CRHR1
SCHEMBL5135433 0.90 C5AR1 (0.46) C5AR1CALM1CAMKK2TLR7
SCHEMBL648971 0.89 C5AR1 (0.42) C5AR1PPARGCRHR1PPARAMMP13
SCHEMBL652044 0.89 C5AR1 (0.43) C5AR1CALM1CAMKK2TLR7PPARG

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1490044-A4 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORP (US) 2008-04-16 EP disclosed
EP-1490044-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2004-12-29 EP disclosed
WO-2003084524-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2003-10-16 WO disclosed